Compare Duke Energy Corp (DUK) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Gilead Sciences, Inc. — how do they compare? Duke Energy Corp trades at $123.14 (market cap $96.05B), while Gilead Sciences, Inc. trades at $135.47 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Duke Energy Corp pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| DUK | GILD | |
|---|---|---|
Market Cap | $96.05B | $168.35B |
Sector | Utilities | Health |
52-Week High | $133.46 | $155.80 |
52-Week Low | $113.99 | $110.56 |
Enterprise Value | $188.56B | $191.42B |
Dividend Yield | 3.52% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
